Windward Bio Debuts on Nasdaq, Shares Surge 68% on IPO Day
Clinical-stage biotech Windward Bio priced its IPO at $17 per share and closed its first trading day at $28.50 on Nasdaq.
Windward Bio, a Shanghai-rooted clinical-stage biotechnology company backed by Qiming Venture Partners, made its public market debut on Nasdaq on November 13, 2026, under the ticker symbol WWB, the company announced Friday.
The immunology-focused biotech priced its initial public offering at $17.00 per share, then saw strong first-day demand push its closing price to $28.50 — a gain of roughly 68 percent from the IPO price, signaling robust investor appetite for the offering.
Read more Inverse Anthropic ETFs Offer Bears Two Ways to Short ANT Stock →
Windward Bio operates as a portfolio company of Qiming Venture Partners, a prominent venture capital firm with deep roots in the Chinese technology and life sciences sectors. The listing marks a significant milestone for the company as it advances its clinical-stage immunology pipeline with access to U.S. public capital markets.
The Nasdaq listing positions Windward Bio alongside a competitive cohort of biotech companies seeking to translate early-stage immunological research into approved therapies. A first-day pop of this magnitude reflects broader market interest in innovative biotech platforms, though clinical-stage companies carry inherent pipeline risk that investors will continue to monitor as the firm progresses its programs.
Continue reading at All Financial Services & Investing.